Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

$1,017,430 $855,415 $4,615,960 $4,196,706

Basic Earnings Per

Share(2) $0.76 $0.64 $3.44 $3.12

Average Number of Common

Shares Outstanding During

Each Period - Basic 1,338,559 1,346,087 1,342,552 1,345,386

Diluted Earnings Per

Share(2) $0.75 $0.63 $3.38 $3.08

Average Number of Common

Shares Outstanding During

Each Period - Diluted 1,367,895 1,379,180 1,374,342 1,374,053

See Notes to Results of Operations and Results of Operations -- As Adjusted.

Results of Operations -- As Adjusted

Wyeth has prepared the following presentation of its results of operations for the three months and full year ended December 31, 2007 and 2006, adjusted where noted below, to exclude productivity initiatives charges and the 2006 income tax adjustment, which are considered certain significant items during the 2007 and 2006 fourth quarter and full year.

The comparative results of operations -- as adjusted are as follows: (In thousands except per share amounts)

(UNAUDITED) -- AS ADJUSTED

Three Months Ended Full Year Ended

12/31/2007 12/31/2006 12/31/2007 12/31/2006

Net Revenue $5,763,526 $5,220,179 $22,399,798 $20,350,655

Cost of Goods Sold(3) 1,629,443 1,448,229 6,069,333 5,458,652

Selling, General and

Administrative

Expenses(3) 1,880,580 1,772,767 6,724,921 6,423,943

Research and Development

Expenses(3) 882,437 913,224 3,256,516 3,097,712

Interest Income, Net (17,071) (6,524) (90,511) (6,646)

Other Income, Net(1) (38,795) (65,951) (290,543) (271,490)

Income Before I
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The Dohmen Company today announced the ... as Chief Science Officer (CSO) of Dohmen Life ... Dr. Floyd will lead Dohmen,s growing regulatory consulting ... and post approval outsourced services in quality, regulatory, ... Floyd brings decades of experience leading global regulatory ...
(Date:9/1/2015)... , Sept. 1, 2015   Medfusion, Inc., ... the relationship between doctors and patients, today announced ... Durham, N.C. -based venture capital firms.   ... business association with Bull City Venture Partners and ... Medfusion Founder and Executive Chairman. "Both firms, experience ...
(Date:9/1/2015)... ... 2015 , ... Research conducted by Synedgen Inc.’s Director for ... of Medicine, Frederick National Laboratory for Cancer Research, and the Centers for Disease ... journal. , Christopher Ryan PhD, of Synedgen, and Aparajita Chatterjee, Daniel M. ...
(Date:8/31/2015)... Calif. (PRWEB) , ... August 31, 2015 , ... ... this year to bring together supply chain risk management and resiliency practitioners with ... develop and share best practices, and be recognized for their innovations and performance ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2